Cargando…

Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022

IMPORTANCE: Adjuvant therapies are often approved based on improvements in disease-, progression-, or relapse-free survival (ie, an event). An important estimate in adjuvant therapies is the cost per event averted. OBJECTIVE: To characterize the costs per event averted of anticancer drugs approved b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mousavi, Idine, Olivier, Timothée, Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187950/ https://www.ncbi.nlm.nih.gov/pubmed/35687338 http://dx.doi.org/10.1001/jamanetworkopen.2022.16058

Ejemplares similares

Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures
por: Neumann, Peter J., et al.
Publicado: (2018)

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials
por: Ahmed, Nibras, et al.
Publicado: (2022)

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted
por: Neumann, Peter J., et al.
Publicado: (2016)

Adherence to the iDSI reference case among published cost-per-DALY averted studies
por: Emerson, Joanna, et al.
Publicado: (2019)

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
por: Olivier, Timothée, et al.
Publicado: (2023)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity
por: Olivier, Timothée, et al.
Publicado: (2023)

Estimation of Potential Deaths Averted From Hypothetical US Income Support Policies
por: Avanceña, Anton L. V., et al.
Publicado: (2022)

Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds
por: Daroudi, Rajabali, et al.
Publicado: (2021)

Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis
por: Chacón, Matías Rodrigo, et al.
Publicado: (2018)

Estimated COVID-19 Cases and Hospitalizations Averted by Case Investigation and Contact Tracing in the US
por: Rainisch, Gabriel, et al.
Publicado: (2022)

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
por: Olivier, Timothée, et al.
Publicado: (2023)

Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non–Small Cell Lung Cancers
por: Parsons, Scott, et al.
Publicado: (2020)

Averting Disease
Publicado: (1860)

Averting Disease
Publicado: (1876)

Association of Research and Development Investments With Treatment Costs for New Drugs Approved From 2009 to 2018
por: Wouters, Olivier J., et al.
Publicado: (2022)

Tebentafusp in first-line melanoma trials: An outperforming outlier
por: Olivier, Timothée, et al.
Publicado: (2022)

A Danger to Be Averted
Publicado: (1892)

Interpretation of active-control randomised trials: the case for a new analytical perspective involving averted events
por: Dunn, David T., et al.
Publicado: (2023)

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

Per Aspenberg, 1949–2018
Publicado: (2018)

Contribution margin per hour of operating room to reallocate unutilized operating room time: a cost-effectiveness analysis
por: Saporito, Andrea, et al.
Publicado: (2021)

Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm
por: Olivier, Timothee, et al.
Publicado: (2021)

Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022
por: Dusetzina, Stacie B., et al.
Publicado: (2023)

The burden of COVID-19 in French Guiana: Vaccine-averted deaths, hospitalizations and costs
por: Nacher, Mathieu, et al.
Publicado: (2023)

Hospital Costs and Fatality Rates of Traumatic Assaults by Mechanism in the US, 2016-2018
por: Barry, Luke E., et al.
Publicado: (2022)

Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials
por: Olivier, Timothée, et al.
Publicado: (2022)

Averting danger from within
por: Bashyam, Hema
Publicado: (2008)

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials
por: Olivier, Timothée, et al.
Publicado: (2022)

Scale-Up of HIV Antiretroviral Therapy and Estimation of Averted Infections and HIV-Related Deaths — Uganda, 2004–2022
por: Dirlikov, Emilio, et al.
Publicado: (2023)

Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018
por: Peet, Evan D., et al.
Publicado: (2022)

Population Growth Inflates the Per-Individual Number of Deleterious Mutations and Reduces Their Mean Effect
por: Gazave, Elodie, et al.
Publicado: (2013)

How has Expenditure on Nicotine Products Changed in a Fast-Evolving Marketplace? A Representative Population Survey in England, 2018–2022
por: Jackson, Sarah E, et al.
Publicado: (2023)

Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted
por: Thomas, Sara L., et al.
Publicado: (2017)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
por: Jairath, Vipul, et al.
Publicado: (2022)

Association Between Hospice Enrollment and Total Health Care Costs for Insurers and Families, 2002-2018
por: Aldridge, Melissa D., et al.
Publicado: (2022)

Industry Involvement and Transparency in the Most Cited Clinical Trials, 2019-2022
por: Siena, Leonardo M., et al.
Publicado: (2023)

Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals
por: Buck, Eva, et al.
Publicado: (2023)

Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials
por: Haslam, Alyson, et al.
Publicado: (2020)

Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review
por: Sharp, John, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1uai9jp4116er2k7c3gru90rdc